KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Gross Margin (2021 - 2025)

Recursion Pharmaceuticals' Gross Margin history spans 5 years, with the latest figure at 59.83% for Q4 2025.

  • For Q4 2025, Gross Margin rose 24127.0% year-over-year to 59.83%; the TTM value through Dec 2025 reached 4.99%, down 1812.0%, while the annual FY2025 figure was 4.99%, 1812.0% down from the prior year.
  • Gross Margin reached 59.83% in Q4 2025 per RXRX's latest filing, up from 183.81% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 100.0% in Q1 2021 to a low of 183.81% in Q3 2025.
  • Average Gross Margin over 5 years is 2.04%, with a median of 12.06% recorded in 2023.
  • The largest YoY upside for Gross Margin was 24127bps in 2025 against a maximum downside of -23750bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 100.0% in 2021, then tumbled by -79bps to 20.74% in 2022, then crashed by -55bps to 9.27% in 2023, then tumbled by -2056bps to 181.43% in 2024, then soared by 133bps to 59.83% in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Gross Margin are 59.83% (Q4 2025), 183.81% (Q3 2025), and 4.88% (Q2 2025).